Parvis Sadjadian

922 total citations
25 papers, 288 citations indexed

About

Parvis Sadjadian is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Parvis Sadjadian has authored 25 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 13 papers in Hematology and 12 papers in Rheumatology. Recurrent topics in Parvis Sadjadian's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers), Eosinophilic Disorders and Syndromes (12 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Parvis Sadjadian is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers), Eosinophilic Disorders and Syndromes (12 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Parvis Sadjadian collaborates with scholars based in Germany, Switzerland and Serbia. Parvis Sadjadian's co-authors include Martin Grießhammer, Kai Wille, Tatjana Becker, Christiane Fuchs, Angela Märten, Frank Griesinger, Matthias Scheffler, Ingo Stehle, Martin Sebastian and David F. Heigener and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Leukemia.

In The Last Decade

Parvis Sadjadian

24 papers receiving 283 citations

Peers

Countries citing papers authored by Parvis Sadjadian

Since Specialization

Citations

This map shows the geographic impact of Parvis Sadjadian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Parvis Sadjadian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Parvis Sadjadian more than expected).

Fields of papers citing papers by Parvis Sadjadian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Parvis Sadjadian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Parvis Sadjadian. The network helps show where Parvis Sadjadian may publish in the future.

Co-authorship network of co-authors of Parvis Sadjadian

This figure shows the co-authorship network connecting the top 25 collaborators of Parvis Sadjadian. A scholar is included among the top collaborators of Parvis Sadjadian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Parvis Sadjadian. Parvis Sadjadian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia 2024 ·European Journal Of Haematology ·Kai Wille, (unknown), (unknown), Parvis Sadjadian, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Christiane Fuchs, Hans‐Joachim Tischler, Martin Grießhammer	4
2	PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN) 2023 ·HemaSphere ·Kai Wille, (unknown), Parvis Sadjadian, Tatjana Becker, (unknown), (unknown), (unknown), (unknown), Christiane Fuchs, Martin Grießhammer	1
3	Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms 2023 ·Hämostaseologie ·Kai Wille, (unknown), Parvis Sadjadian, Tatjana Becker, (unknown), (unknown), (unknown), (unknown), Christiane Fuchs, Martin Grießhammer	5
4	Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies 2021 ·Annals of Hematology ·(unknown), Parvis Sadjadian, Tatjana Becker, (unknown), (unknown), (unknown), (unknown), (unknown), Christiane Fuchs, Martin Grießhammer, Kai Wille	14
5	The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera 2021 ·European Journal Of Haematology ·Kai Wille, (unknown), Parvis Sadjadian, Tatjana Becker, (unknown), (unknown), Martin Grießhammer	4
6	A review of hydroxyurea-related cutaneous adverse events 2021 ·Expert Opinion on Drug Safety ·Martin Grießhammer, Kai Wille, Parvis Sadjadian, Frank Stegelmann, Konstanze Döhner	7
7	Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN 2020 ·Leukemia ·Frank Stegelmann, Kai Wille, (unknown), Christiane Fuchs, Stefanie Schauer, Parvis Sadjadian, Tatjana Becker, (unknown), Hartmut Döhner, Rudolf Stadler, (unknown), Konstanze Döhner, Martin Grießhammer	9
8	Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety 2020 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), Florian H. Heidel, Parvis Sadjadian, Tatjana Becker, (unknown), Andreas Hochhaus, Martin Grießhammer, Kai Wille	6
9	Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms 2020 ·Annals of Hematology ·(unknown), Parvis Sadjadian, Tatjana Becker, (unknown), (unknown), (unknown), Martin Grießhammer, Kai Wille	17
10	Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations 2020 ·Cancers ·Parvis Sadjadian, Kai Wille, Martin Grießhammer	19
11	Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) 2019 ·Annals of Oncology ·Frank Griesinger, Wilfried Eberhardt, Harald-Robert Bruch, (unknown), (unknown), Norbert Marschner, Martina Jänicke, (unknown), (unknown), (unknown), (unknown), A. Hipper, Wilko Weichert, Parvis Sadjadian, Martin Metzenmacher, Wolfgang Gleiber, Martin Sebastian, Mike Thomas	1
12	High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation 2018 ·Annals of Hematology ·Kai Wille, Parvis Sadjadian, Tatjana Becker, (unknown), (unknown), Christiane Fuchs, Martin Grießhammer	25
13	Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy 2018 ·Expert Review of Hematology ·Martin Grießhammer, Parvis Sadjadian, Kai Wille	31
14	Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod 2017 ·Annals of Oncology ·Michael Thomas, Santiago Ponce-Aix, Alejandro Navarro, Jorge Riera Knorrenschild, Manuel Schmidt, (unknown), Emanuelly Varea Maria Wiegert, M. Dómine Gómez, Jens Kollmeier, Parvis Sadjadian, (unknown), Rudolf M. Huber, M. Wolf	5
15	A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer 2017 ·Investigational New Drugs ·Michael Thomas, Parvis Sadjadian, Jens Kollmeier, (unknown), (unknown), J. Richard Trout, Michele Gargano, Myra L. Patchen, Richard M. Walsh, Martin Béliveau, Jean‐Francois Marier, Nandita Bose, Keith Gorden, Folker Schneller	46
16	P3.02c-044 Nivolumab-Response in a Patient with Advanced Squamous NSCLC Occurring Simultaneously with SIAD 2017 ·Journal of Thoracic Oncology ·Parvis Sadjadian, Martin Grießhammer	0
17	Thrombozytose und Thrombozytopenie – Ursachen und klinische Bedeutung 2017 ·DMW - Deutsche Medizinische Wochenschrift ·Kai Wille, Parvis Sadjadian, Martin Grießhammer	5
18	The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium 2017 ·Expert Opinion on Pharmacotherapy ·Martin Grießhammer, Parvis Sadjadian	13
19	Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors 2015 ·The Oncologist ·David F. Heigener, Christian Schumann, Martin Sebastian, Parvis Sadjadian, Ingo Stehle, Angela Märten, (unknown), Frank Griesinger, Matthias Scheffler	56
20	Endogenous anti-β-glucan antibodies as a potential predictive biomarker for clinical response to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients. 2014 ·Journal of Clinical Oncology ·Nandita Bose, Mary A. Antonysamy, Myra L. Patchen, (unknown), (unknown), Michele Gargano, Keith Gorden, Steven Leonardo, Richard M. Walsh, (unknown), (unknown), (unknown), (unknown), (unknown), Anissa Chan, (unknown), Richard D. Huhn, Michaël Thomas, Parvis Sadjadian, Folker Schneller	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact